BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of ...

-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases - - BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune dis ...

The investigation concerns whether Caribou and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On June 2, 2024, Caribou issued a press release announcing that the Company had "presented updated clinical data from the ongoing ANTLER Phase 1 trial that indicates a single dose of CB-010, a readily available, offthe-shelf anti-CD19 CAR-T cell therapy with a PD-1 knockout, has the potential to rival the safety, efficacy, and durability of approved a ...

-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation of improved o ...

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -17.95%. A quarter ago, it was expected that this company would post a loss of $0.22 per share when it actually produced a loss of $0.39, delivering a surprise of -77.27%.Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Registrant's telephone number, including area code: (510) 982-6030 ______________________________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par ...

Exhibit 99.1 Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- $345.9 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into Q1 2026 -- "We continue to focus on advancing four clinical-stage programs, including the parallel development of ...

BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois. The ANTLER poster will provide initial dose expansion data. Details of the poster presentation are as follows: Title: A CRISPR-edited a ...

Solskin Caribou Biosciences, Inc. (NASDAQ:CRBU) is gearing up to present initial dose expansion data from its ongoing phase 1 ANTLER study. This particular early-stage study uses CB-010 for the treatment of patients with 2nd-line relapsed or refractory large B cell lymphoma [r/r LBCL]. Positive data from the dose-escalation portion of the study was already released. What investors can look forward to regarding the advancement of this program would be two catalysts in particular. The first catalyst would be ...

-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases -- -- Advancing ANTLER Phase 1 trial for 2L LBCL; initial dose expansion data to be shared at a medical congress in Q2 2024 -- -- Conference call and webcast scheduled for today at 5 ...